Ardelyx ’s first-in-class NHE3 blocker Tenapanor boasts positive phase III data

On May 12, Ardelyx, a US-based clinical-stage company focused on the development of treatments for cardio-renal and gastrointestinal (GI) diseases, announced positive top-line results from the T3MPO-1 Phase III study for the use of tenapanor to treat …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news